Cargando…

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST

The predictive value of longitudinal biomarker data (vascular endothelial growth factor (VEGF), soluble VEGF receptor (sVEGFR)-2, sVEGFR-3, and soluble stem cell factor receptor (sKIT)) for tumor response and survival was assessed based on data from 303 patients with imatinib-resistant gastrointesti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hansson, E K, Amantea, M A, Westwood, P, Milligan, P A, Houk, B E, French, J, Karlsson, M O, Friberg, L E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852160/ https://www.ncbi.nlm.nih.gov/pubmed/24257372 http://dx.doi.org/10.1038/psp.2013.61

Ejemplares similares

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST
por: Hansson, E K, et al.
Publicado: (2013)

Unraveling the Angiogenic Puzzle: Pre-Treatment sVEGFR1 and sVEGFR2 Levels as Promising Prognostic Indicators in Early-Stage Breast Cancer Patients
por: Zarychta, Elżbieta, et al.
Publicado: (2023)

Doxycycline Reduces Plasma VEGF-C/sVEGFR-3 and Improves Pathology in Lymphatic Filariasis
por: Debrah, Alexander Yaw, et al.
Publicado: (2006)

AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice
por: Kujala, Anni, et al.
Publicado: (2022)

Gene polymorphisms and serum levels of sVEGFR-1 in patients with systemic lupus erythematosus
por: Yuan, Zhi-Chao, et al.
Publicado: (2020)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

sVEGFR1 Is Enriched in Hepatic Vein Blood—Evidence for a Provisional Hepatic Factor Candidate?
por: Spearman, Andrew D., et al.
Publicado: (2021)

The Role of Angiogenesis Factors in the Formation of Vascular Changes in Scleroderma by Assessment of the Concentrations of VEGF and sVEGFR2 in Blood Serum and Tear Fluid
por: Waszczykowska, Arleta, et al.
Publicado: (2020)

A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use
por: Wu, Florence T H, et al.
Publicado: (2010)

Commentary: sVEGFR1 Is Enriched in Hepatic Vein Blood—Evidence for a Provisional Hepatic Factor Candidate?
por: Putotto, Carolina, et al.
Publicado: (2021)

Predictive and diagnostic value of serum sVEGFR-1 level in women with preeclampsia: A prospective controlled study
por: Şalk, Sultan, et al.
Publicado: (2022)

Evaluation of the effects of different treatment modalities on angiogenesis in heart failure patients with reduced/mid-range ejection fraction via VEGF and sVEGFR-1
por: Erturk, Ismail, et al.
Publicado: (2018)

The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma
por: Abou Faycal, Cherine, et al.
Publicado: (2018)

Hypoxia down-regulates sFlt-1 (sVEGFR-1) expression in human microvascular endothelial cells by a mechanism involving mRNA alternative processing
por: Ikeda, Takayuki, et al.
Publicado: (2011)

Regulation of soluble vascular endothelial growth factor receptor (sFlt-1/sVEGFR-1) expression and release in endothelial cells by human follicular fluid and granulosa cells
por: Gruemmer, Ruth, et al.
Publicado: (2005)

Secretion of Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR1/sFlt1) Requires Arf1, Arf6, and Rab11 GTPases
por: Jung, Jae-Joon, et al.
Publicado: (2012)

Correction: Secretion of Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR1/sFlt1) Requires Arf1, Arf6, and Rab11 GTPases
por: Jung, Jae-Joon, et al.
Publicado: (2012)

Matrix Metalloproteinases MMP-2 and MMP-9, Their Inhibitors TIMP-1 and TIMP-2, Vascular Endothelial Growth Factor and sVEGFR-2 as Predictive Markers of Ischemic Retinopathy in Patients with Systemic Sclerosis—Case Series Report
por: Waszczykowska, Arleta, et al.
Publicado: (2020)

Pre‐diagnostic levels of sVEGFR2, sTNFR2, sIL‐2Rα and sIL‐6R are associated with glioma risk: A nested case–control study of repeated samples
por: Wu, Wendy Yi‐Ying, et al.
Publicado: (2022)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

VEGF-VEGFR Signals in Health and Disease
por: Shibuya, Masabumi
Publicado: (2014)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
por: Scartozzi, M, et al.
Publicado: (2013)

Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
por: Wang, Min, et al.
Publicado: (2019)

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
por: Dziobek, Konrad, et al.
Publicado: (2019)

Off-the-wall skits with phrasal verbs /
por: Trenga, Bonnie
Publicado: (2003)

Targeting VEGF/VEGFR to Modulate Antitumor Immunity
por: Yang, Ju, et al.
Publicado: (2018)

Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case Reports
por: Prochilo, Tiziana, et al.
Publicado: (2013)

Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells
por: Garvin, S, et al.
Publicado: (2005)

Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer
por: Bando, H, et al.
Publicado: (2005)

Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis
por: Kilvaer, Thomas K., et al.
Publicado: (2010)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

The role of the VEGF-C/VEGFR-3 axis in cancer progression
por: Su, J-L, et al.
Publicado: (2007)

Genetic variations in VEGF and VEGFR2 and glioblastoma outcome
por: Sjöström, S., et al.
Publicado: (2010)

Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15
por: Yang, Gui-Li, et al.
Publicado: (2018)

The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy
por: Mabeta, Peace, et al.
Publicado: (2022)

Structure-Based Design of Peptides Targeting VEGF/VEGFRs
por: Di Stasi, Rossella, et al.
Publicado: (2023)

Seasonal expressions of VEGF and its receptors VEGFR1 and VEGFR2 in the prostate of the wild ground squirrels (Spermophilus dauricus)
por: Yao, Yuchen, et al.
Publicado: (2021)

Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis
por: Miao, Chenkui, et al.
Publicado: (2017)

Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
por: Peach, Chloe J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8lkb7q4bs470u4ga0bh1paqljg